Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Liabilities and Shareholders Equity (2016 - 2021)

GT Biopharma (GTBP) has disclosed Liabilities and Shareholders Equity for 12 consecutive years, with $35.8 million as the latest value for Q3 2021.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 3803.82% to $35.8 million in Q3 2021 year-over-year; TTM through Dec 2021 was $103.0 million, a 1197.98% increase, with the full-year FY2020 number at $5.7 million, up 1329.55% from a year prior.
  • Liabilities and Shareholders Equity was $35.8 million for Q3 2021 at GT Biopharma, down from $39.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $257.3 million in Q1 2018 to a low of $42000.0 in Q2 2017.
  • A 5-year average of $67.4 million and a median of $25.6 million in 2019 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 1017372.0% in 2017, then plummeted 98.84% in 2020.
  • GT Biopharma's Liabilities and Shareholders Equity stood at $254.4 million in 2017, then plummeted by 89.57% to $26.5 million in 2018, then plummeted by 98.51% to $396000.0 in 2019, then soared by 1329.55% to $5.7 million in 2020, then soared by 532.36% to $35.8 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Liabilities and Shareholders Equity are $35.8 million (Q3 2021), $39.6 million (Q2 2021), and $27.6 million (Q1 2021).